What question did this study set out to answer?

The research aims to assess how tolebrutinib affects disability worsening compared to its impact on relapse prevention in patients with multiple sclerosis.

April 10, 2026

Uncoupling Relapse Reduction and Disability Progression

Key Points

The research aims to assess how tolebrutinib affects disability worsening compared to its impact on relapse prevention in patients with multiple sclerosis.
Comparative analysis of tolebrutinib and other disease-modifying therapies (DMTs)
Evaluation of confirmed disability worsening (CDW) rates
Assessment of relapse prevention efficacy
Tolebrutinib shows different effects on disability worsening compared to relapse prevention
Overall improvement in relapse rates was noted, though disability worsening did not align with these effects

Abstract

The aim of this study was to evaluate whether the treatment effects of tolebrutinib on confirmed disability worsening (CDW) diverge from its effects on relapse prevention compared with other disease-modifying therapies (DMTs) for relapsing multiple sclerosis (MS).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Alessio Signori

Noemi Montobbio

Francesca Bovis

Journals

Neurology Clinical Practice

Actions

Institutions

University of Genoa

Ospedale Policlinico San Martino

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Uncoupling Relapse Reduction and Disability Progression

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider